Want to see HK:2196 full AI Analyst Report?

Shanghai Fosun Pharmaceutical (Group) Co (2196) Price & Analysis

5 Followers

2196 Stock Chart & Stats

HK$16.07

HK$0.13(0.81%)

At close: Jul 27 4:00 PM EDT

HK$16.07

HK$0.13(0.81%)

Day’s Range― - ―

52-Week RangeHK$14.90 - HK$29.00

Previous CloseN/A

Volume1.85M

Average Volume (3M)8.63M

Market Cap

HK$69.57B

Enterprise ValueHK$84.21K

Total Cash (Recent Filing)HK$15.29B

Total Debt (Recent Filing)HK$31.86B

Price to Earnings (P/E)18.3

Beta1.11

Next Earnings

Aug 26, 2026

EPS Estimate

0.42

Next Dividend Ex-DateN/A

Dividend Yield2.68%

Share Statistics

EPS (TTM)1.61

Shares Outstanding551,940,500

10 Day Avg. Volume5,166,409

30 Day Avg. Volume8,626,817

Financial Highlights & Ratios

PEG Ratio0.74

Price to Book (P/B)0.95

Price to Sales (P/S)1.15

P/FCF Ratio60.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$25.15

Price Target Upside56.50% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)1.47

Revenue Forecast (FY)HK$43.51B

Bulls Say, Bears Say

Bulls Say

Revenue Rebound & Gross MarginA 158% TTM revenue rebound coupled with ~49% gross margin signals durable recovery and a favorable product mix. Sustained higher top-line with strong gross margin enhances ability to cover fixed costs, fund commercialization and R&D, and supports medium-term earnings resilience.

Diversified Healthcare ModelOperating across manufacturing, distribution and healthcare services provides diversified, complementary revenue streams. That structural mix reduces single-product exposure, stabilizes cash flows across cycles, and enables channel control and cross-selling that support resilience over the next several months.

Manageable Leverage And Improving ROEModerate leverage (D/E ~0.75) affords capacity to fund growth while keeping solvency risk in check. An improving ROE (~7%) points to recovering capital efficiency; together these structural balance-sheet characteristics support measured investment and strategic execution over coming quarters.

Bears Say

Weak Cash ConversionFCF at ~24% of net income and a volatile free-cash-history mean reported profits are not reliably converting to cash. This limits durable funding for capex, R&D, dividends and M&A, raising execution and liquidity risk if working capital or investment needs increase in the medium term.

Moderate Operating Margins; Downward EBITDA TrendEBIT margin near 7.3% and a declining EBITDA margin versus earlier years indicate persistent cost pressure or adverse mix. Moderate margins constrain the company's ability to convert revenue growth into durable net cash and profit expansion, limiting reinvestment capacity over the next 2–6 months.

Returns Still Below Prior PeakROE improvement is encouraging, but remaining below 2021–2022 levels shows the company has not fully restored historic return on capital. Persistently muted returns can limit long-term investor returns and suggest structural or competitive headwinds that may persist into the medium term.

Shanghai Fosun Pharmaceutical (Group) Co News

Fosun Pharma Subsidiary Advances COPD Drug FXS7553 Into Phase II Trial in China

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has issued an announcement. Shanghai Fosun Pharmaceutical has announced that...

2d ago

Fosun Pharma Sets August Board Meeting to Approve 2026 Interim Results

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has issued an announcement. Shanghai Fosun Pharmaceutical (Group) Co., Ltd....

2d ago

Fosun Pharma Wins NMPA Approval for New Levosalbutamol Nebuliser Therapy

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has provided an update. Shanghai Fosun Pharmaceutical has announced that...

8d ago

Fosun Pharma Subsidiary Wins China Approval for Heart Failure Injection

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an announcement. Shanghai Fosun Pharmaceutical said its subsidiary...

8d ago

Fosun Pharma Subsidiary Wins Approval for Pediatric Constipation Drug in China

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has provided an announcement. Shanghai Fosun Pharmaceutical’s subsidiary Suzhou Erye...

12d ago

Fosun Pharma Subsidiary Wins Approval for New Type 2 Diabetes Combination Drug

An update from Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) is now available. Shanghai Fosun Pharmaceutical (Group)...

12d ago

Fosun Pharma Unit Wins NMPA Nod for Parkinson’s Drug Trial

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has provided an announcement. Shanghai Fosun Pharmaceutical said its subsidiary...

22d ago

Fosun Pharma Wins NMPA Nod for FXR0906 Hypertriglyceridemia Trial

The latest announcement is out from Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ). Shanghai Fosun Pharmaceutical’s subsidiary...

1M ago

Fosun Pharma Subsidiary Wins Approval for New Traditional Chinese Medicine Granules

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an update. Shanghai Fosun Pharmaceutical said its subsidiary...

2M ago

Fosun Pharma Moves Ahead With Spin-Off Listing of Fosun Adgenvax in Hong Kong

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) just unveiled an update. Shanghai Fosun Pharmaceutical (Group) Co., Ltd....

2M ago

Shanghai Fosun downgraded to Hold from Buy at HSBC

HSBC downgraded Shanghai Fosun to Hold from Buy with a price target of HK$20, down from HK$40. The...

3y ago

Syneos Health partners with Fosun Pharma USA to launch serplulimab

Syneos Health (SYNH) announced a strategic partnership with Fosun Pharma USA (SFOSF). As part of the partnership, Syneos...

4y ago

SYNH

2196 FAQ

What was Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price range in the past 12 months?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H lowest stock price was HK$14.90 and its highest was HK$29.00 in the past 12 months.

What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap is HK$69.57B.

When is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date is Aug 26, 2026 which is in 11 days.

How were Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s earnings last quarter?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H released its earnings results on Apr 28, 2026. The company reported HK$0.384 earnings per share for the quarter, beating the consensus estimate of HK$0.378 by HK$0.006.

Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H overvalued?

According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pay dividends?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pays a Annually dividend of HK$0.45 which represents an annual dividend yield of 2.68%. See more information on Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H dividends here

What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate is 0.42.

How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H have?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 551,940,500 shares outstanding.

What happened to Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price movement after its last earnings report?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H reported an EPS of HK$0.384 in its last earnings report, beating expectations of HK$0.378. Following the earnings report the stock price went up 1.272%.

Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?

Currently, no hedge funds are holding shares in HK:2196

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score

Neutral

Fundamentals

Return on Equity

2.68%

Trailing 12-Months

Asset Growth

9.40%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKEX: 2196) is a China-based healthcare group engaged in pharmaceutical manufacturing and commercialization, pharmaceutical distribution, and healthcare/medical services. The company develops, produces, and sells prescription drugs and other pharmaceutical products across multiple therapeutic areas, operates pharmaceutical distribution activities through subsidiaries, and has investments and operations spanning medical devices/diagnostics and healthcare service offerings (e.g., hospital-related businesses).

Shanghai Fosun Pharmaceutical (Group) Co (2196) Earnings & Revenues

Historic Earnings Reports

2196 Stock 12 Month Forecast

Average Price Target

HK$25.15

▲(56.50% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"HK$13","18":"HK$18","23":"HK$23","28":"HK$28","33":"HK$33"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$25.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$18.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,18,23,28,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.42,17.61846153846154,18.81692307692308,20.015384615384615,21.213846153846156,22.412307692307692,23.61076923076923,24.80923076923077,26.00769230769231,27.206153846153846,28.404615384615383,29.603076923076923,30.80153846153846,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.42,17.091538461538462,17.763076923076923,18.434615384615384,19.10615384615385,19.77769230769231,20.44923076923077,21.12076923076923,21.79230769230769,22.463846153846156,23.135384615384616,23.806923076923077,24.478461538461538,{"y":25.15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.42,16.564615384615387,16.70923076923077,16.853846153846156,16.99846153846154,17.143076923076926,17.28769230769231,17.432307692307692,17.576923076923077,17.72153846153846,17.866153846153846,18.01076923076923,18.155384615384616,{"y":18.3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.341,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.247,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.097,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.189,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.813,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.032,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.343,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.827,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.918,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.603,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.695,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.709,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.42,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >